100 filings
Page 4 of 5
8-K
u6gcybh4ihuxpx
3 Aug 20
Other Events
8:33am
8-K
1todx5 qvnklypc93rbb
23 Jun 20
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
phy2i59emju6
16 Jun 20
Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development
8:20am
8-K
pl9mhuk 91o0vdo6h9i
28 May 20
Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
4:08pm
8-K
ddfww g15
8 May 20
Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
4:22pm
8-K
zjhth7ibvtxn5u3h
4 May 20
Genprex Issues April 2020 Shareholder Letter
4:30pm
8-K
cn4dg3ywbdpnu w0
28 Apr 20
Unregistered Sales of Equity Securities
4:27pm
8-K
zwfkhnolk0lyq7dle
21 Apr 20
Departure of Directors or Certain Officers
4:47pm
8-K
6bngqfkkgpbecshbivlb
24 Mar 20
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders
9:20am
8-K
h7lompaaxr3iilsv
23 Mar 20
Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives
3:52pm
8-K
rn0u59
18 Mar 20
Unregistered Sales of Equity Securities
5:09pm
8-K
jf5458t82a22aou
20 Feb 20
Entry into a Material Definitive Agreement
4:32pm
8-K
r9pq0d
18 Feb 20
Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
10:58am
8-K
fyu7noj4k60l3r6
6 Feb 20
Other Events
8:20am
8-K
ncgo4sfmhzq
5 Feb 20
Other Events
9:33am
8-K
v66uozxijai1705mmml0
5 Feb 20
Other Events
9:22am
8-K
4ibchw
31 Jan 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
3px55o6yyvism70d9j1q
24 Jan 20
Entry into a Material Definitive Agreement
5:05pm
8-K
94s4n9m1pxre63ofgw
21 Jan 20
Genprex Receives U.S. FDA Fast Track Designation
9:15am
8-K
sckq1mffc8c
17 Jan 20
Entry into a Material Definitive Agreement
5:13pm